Value
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 6.2 |
| P/S | 5.7 |
| EV/EBITDA | 2.7 |
| Fwd P/E | 7.8 |
| PEG | 9.4 |
| Analyst target | 3.0 |
- ▸Forward P/E: 15.5x
- ▸PEG: 0.59
EXEL · Why this verdict
Why Exelixis (EXEL) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score6.3/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
Exelixis is a wide-moat, high-quality oncology compounder (ROE 44%, 35% margins, 4/4 earnings beats), but the price of $64.53 is already 22.5% above the $49.98 analyst target and sits 1.5% from its 52-week high, with earnings due in 5 days.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Exelixis earns excellent returns: ROE of 44%, margins of 35%, a wide economic moat and a Piotroski F-Score of 9/9. Quality breakdown | ROE should stay above 35% and quality score above 8.5 over the next four quarters. | →Stable |
| CounterThe franchise rests on a single product, cabozantinib, so patent or competition changes could erode margins quickly regardless of current quality scores. | ||
Earnings beat estimates in each of the last 4 quarters, while revenue grew from $555.4M to $628.7M over the past year. Bull case | Quarterly revenue should exceed the $649.7M estimate and extend the beat streak at the 2026-10-29 report. | →Stable |
| CounterAfter a 4/4 streak the bar is high and a stock near its 52-week high has little cushion for an inline result. | ||
Revenue depends on cabozantinib, flagged as a high product concentration risk in a binary biotechnology industry. Bear case | Revenue growth should stay above 5% without new cabozantinib pricing or competitive pressure. | ↓Deteriorating |
| CounterPipeline progress could diversify revenue, and a dominant franchise has so far produced steady growth and strong cash flow. | ||
At $64.53 the stock is 22.5% above the $49.98 analyst target, the target is reached, and the stock is 1.5% from its 52-week high with 11.6% downside. Upside pct | Analysts should raise the target above $64.53, or price should ease back toward the $62.93 entry level. | →Stable |
| CounterAnalyst targets lag a rerating, and strong momentum (7.2) with rising volume suggests the market is pricing in a better outlook than the analysts. | ||
Exelixis earns excellent returns: ROE of 44%, margins of 35%, a wide economic moat and a Piotroski F-Score of 9/9.
→StableQuality breakdown
- Expectation
- ROE should stay above 35% and quality score above 8.5 over the next four quarters.
CounterThe franchise rests on a single product, cabozantinib, so patent or competition changes could erode margins quickly regardless of current quality scores.
Earnings beat estimates in each of the last 4 quarters, while revenue grew from $555.4M to $628.7M over the past year.
→StableBull case
- Expectation
- Quarterly revenue should exceed the $649.7M estimate and extend the beat streak at the 2026-10-29 report.
CounterAfter a 4/4 streak the bar is high and a stock near its 52-week high has little cushion for an inline result.
Revenue depends on cabozantinib, flagged as a high product concentration risk in a binary biotechnology industry.
↓DeterioratingBear case
- Expectation
- Revenue growth should stay above 5% without new cabozantinib pricing or competitive pressure.
CounterPipeline progress could diversify revenue, and a dominant franchise has so far produced steady growth and strong cash flow.
At $64.53 the stock is 22.5% above the $49.98 analyst target, the target is reached, and the stock is 1.5% from its 52-week high with 11.6% downside.
→StableUpside pct
- Expectation
- Analysts should raise the target above $64.53, or price should ease back toward the $62.93 entry level.
CounterAnalyst targets lag a rerating, and strong momentum (7.2) with rising volume suggests the market is pricing in a better outlook than the analysts.
Per-dimension breakdown
Quality
9.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 10.0 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 9.5 |
| FCF quality | 6.3 |
| Moat | 9.0 |
| Rule of 40 | 7.1 |
| Piotroski F | 10.0 |
- ▸Excellent ROE: 44%
- ▸Strong margins: 35%
- ▸Wide economic moat
- ▸Compounder quality: strong returns + growth
Growth
6.2/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 5.2 |
| EPS growth | 7.2 |
Momentum
6.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.8 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 1.7 |
- ▸Overbought (RSI 84)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.3 |
| Price target | 2.7 |
| erm sentiment | 5.5 |
- ▸Below analyst target
Insider
4.0/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 3.9 |
| notable moves | 3.0 |
- ▸Negligible insider selling — $526,512 (0.003% of mkt cap)
Peer rank
5.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.7 |
| quality rank | 9.0 |
| growth rank | 4.1 |
- ▸Superior ROE vs peers
- ▸Best-in-class margins
Technical
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.1 |
| support resistance | 0.1 |
| 52w position | 10.0 |
Risk (lower is worse)
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.0 |
| days to cover | 0.0 |
| volatility | 6.9 |
| put call | 10.0 |
| implied vol | 3.5 |
| max pain risk | 3.0 |
| beta | 10.0 |
| debt equity | 9.6 |
- ▸Short squeeze setup: 15% short, quality 7.5
- ▸Above max pain $25
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 9.0 |
- ▸Perfect beat streak: 4Q
- ▸Earnings today
How the verdict was assembled
Engine trigger
Earnings today. Wait until post-earnings.
Engine technical detail
verdict_path:
L3:NEWS_BLOCK|ENTRY_STICKY:WITHIN_BANDPassed (5)
- MOMENTUM:6.9>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- ASYMMETRY:-1.8=NEGATIVE
- EARNINGS_PROXIMITY:0d<=7d
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-1.76
Upside
-24.6%
Downside
14.0%
Sizing output
STARTER
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
A recent news event triggered an L3 news-block on the verdict path. Trigger: Earnings today. Wait until post-earnings. The 10-dimension scores remain Quality at 9.2 (strongest), but ASYMMETRY:-1.8=NEGATIVE also fails — the news block is the proximate trigger, not the sole driver.
The strongest dimensions are Quality at 9.2, Catalyst at 7.2, and Momentum at 6.9; the weakest are Technical at 3.7, Insider at 4.0, and Sentiment at 5.3. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of -1.76 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Wide Moat Compounder Quality
Trip ifOperating margin falls below 25% from the current 35%.
- P2Perfect Earnings Beat Streak
Trip ifEPS surprise stays below 0% for 2 consecutive quarters.
- P3Cabozantinib Concentration
Trip ifQuarterly revenue falls below $600M, under the $628.7M current level.
- P4Price Above Analyst Target
Trip ifShare price drops to $59.73 or lower, the stop-loss level, from the current $64.53.